Cytokinetics CEO sells 7,500 shares at $70.24
Rhea-AI Filing Summary
CYTOKINETICS INC (CYTK) reported that President & CEO Robert I. Blum exercised options and sold shares in a coordinated transaction under a Rule 10b5-1 trading plan. He exercised 7,500 Non-Qualified Stock Options at an exercise price of $10.60 per share, receiving 7,500 common shares, and on the same date sold 7,500 common shares at $70.24 per share. Following the option exercise, he held 164,245 shares of common stock directly, plus indirect holdings of 2,083 shares in each of two irrevocable trusts.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,500 shares ($447K approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Blum Robert I
Role
President & CEO
Sold
7,500 shs ($527K)
Approx. gross sale proceeds
$527K
Approx. exercise cost
$80K
Approx. pre-tax spread
$447K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 7,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,500 | $10.60 | $80K |
| Sale | Common Stock | 7,500 | $70.24 | $527K |
| holding | Common Stock F1 | -- | -- | -- |
| holding | Common Stock F2 | -- | -- | -- |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 164,245 shares (Direct);
Common Stock — 377,820 shares (Direct);
Common Stock — 2,083 shares (Indirect, by Trust 1);
Common Stock — 2,083 shares (Indirect, by Trust 2)
Footnotes (2)
- F1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
- F2. Shares held by The Brittany Blum 2003 Irrevocable Trust.
Key Figures
Options exercised: 7,500 shares
Option exercise price: $10.60 per share
Shares sold: 7,500 shares
+4 more
7 metrics
Options exercised
7,500 shares
Non-Qualified Stock Option (Right to Buy) exercised on August 31, 2026
Option exercise price
$10.60 per share
Exercise price of Non-Qualified Stock Option for 7,500 shares
Shares sold
7,500 shares
Common Stock sale on August 31, 2026
Sale price
$70.24 per share
Price for 7,500 CYTOKINETICS common shares sold
Direct holdings after exercise
164,245 shares
Total common stock directly owned by Robert Blum after derivative transaction
Indirect holdings by Trust 1
2,083 shares
Common Stock held by The Bridget Blum 2003 Irrevocable Trust
Indirect holdings by Trust 2
2,083 shares
Common Stock held by The Brittany Blum 2003 Irrevocable Trust
Key Terms
Non-Qualified Stock Option (Right to Buy), Irrevocable Trust, indirect ownership
3 terms
Non-Qualified Stock Option (Right to Buy) financial
"security_title: Non-Qualified Stock Option (Right to Buy)"
Irrevocable Trust financial
"Shares held by The Bridget Blum 2003 Irrevocable Trust."
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
indirect ownership financial
"ownership_type: indirect, nature_of_ownership: by Trust 1"
FAQ
What did CYTK President & CEO Robert Blum report on this Form 4 for CYTK?
He exercised 7,500 options at $10.60 per share into 7,500 CYTOKINETICS common shares and sold 7,500 shares at $70.24 per share, in transactions made under a Rule 10b5-1 trading plan.
What options did Robert Blum exercise in CYTK stock?
He exercised a Non-Qualified Stock Option for 7,500 shares of CYTOKINETICS common stock at an exercise price of $10.60 per share. The option was originally exercisable from March 28, 2017 and expires on February 28, 2027.
What indirect CYTK holdings does Robert Blum report through trusts?
He reports indirect ownership of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust, as noted in the Form 4 footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
